The proportions of DCCHs with claims for breast cancer-related service fees were 15.2% (range: 0.0%–50.0%) for cancer genome profiling tests, 62.0% (range: 0.0%–100.0%) for cancer BRCA1/2 genetic tests, and 92.8% (range: 60.0%–100.0%) for patient support system enhancement. The gene discussed is BRCA1; the disease is cancer.